Abstract
This report confirms experimental data on direct inhibitory effects of LH–RH agonists in growth control of human prostate cancer cells. The patient had hormone–refractory prostatic carcinoma after hormonal therapy, including orchiectomy, and responded successfully to a 6–month treatment with goserelin acetate (3.6 mg depot s.c.). The treatment has led to a reduction of tumor mass and metastases as well as an improvement in the patient’s paraclinical indicators and general status. The remission lasted 14 months. The treatment still continues.
References
1.
Stenberg CN: Hormone refractory metastatic prostate cancer. Ann Oncol 1992;3:331–335.
2.
Mahler C, Denis L: Hormone refractory disease. Semin Surg Oncol 1995;11:77–83.
3.
Waymont B, Lynch TH, Dunn JA, Emtage LA, Arkell DG, Wallace DM, Blackledge GRP: Phase III randomised study of Zoladex versus Stilboestrol in the treatment of advanced prostate cancer. Br J Urol 1992;69:614–620.
4.
Denis L, Nove P: Bilateral orchiechtomy in patients with progressive advanced prostatic cancer. Semin Surg Oncol 1995;11:77–83.
5.
Dondi D, Limonta P, Moretti RM, Marelli MM, Garattini E, Motta M: Antiproliferative effects of luteinizing hormone–releasing hormone (LHRH) agonists on human androgen–independent prostate cancer cell line DU 145: Evidence for an autocrine–inhibitory LHRH loop. Cancer Res 1994;54:4091–4095.
6.
Limonta P, Dondi D, Moretti RM, Maggi R, Motta M: Antiproliferative effects of luteinizing hormone–releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 1992;75:207–212.
7.
Loop SM, Gorder CA, Lewis SM, Saiers JH, Drivadhal RH, Ostenson RC: Growth inhibition of human prostate tumor cells by an agonist of gonadotrophin–releasing hormone. Prostate 1995;26:179–188.
8.
Schally AV, Redding TW: Use of LH–RH analogs for the treatment of prostatic cancer: Combination therapy and direct effects; in Klijn JGM et al. (eds): Hormonal Manipulation of Cancer: Peptides, Growth Factors, and New (Anti)Steroidal Agents. New York, Raven Press, 1987, pp 273–279.
9.
Qayum A, Gullik W, Clayton RC, Sikora K, Waxman J: The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br J Cancer 1990;62:96–99.
10.
Sica G, Iacopino F, Settesoldi D, Zelano G: Effect of leuprorelin acetate on cell growth and prostate–specific antigen gene expression in human prostatic cancer cells. Eur Urol 1999; 35(suppl 1):2–8.
11.
Marelli MM, Moretti RM, Dondi D, Motta M, Limonta P: Luteinizing hormone–releasing hormone agonists interfere with the mitogenic activity of the insulin–like growth factor system in androgen–independent prostate cancer cells. Endocrinology 1999;144:329–334.
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
